AltMountain

Deerfield Management Company

New York, NY · CRD 157876
Hedge fund manager

Deerfield Management Company is an SEC-registered investment adviser based in New York, NY that reports managing 11 hedge funds on Form ADV. It reports $19.1 billion in regulatory assets under management. Its private funds, of all types, hold $19.2 billion in gross assets. Its disclosed U.S. stock holdings returned an estimated +17.7% 2026 YTD through Jun 30 (S&P 500: +9.5%), based on 13F filings. Over a longer period they returned an estimated +66.2% from Q3 2025 to Q2 2026, compared with +20.9% for the S&P 500, based on 13F filings.

Regulatory assets under management
$19.1 billionForm ADV Item 5.F
Gross assets of private funds
$19.2 billionAll private fund types, Form ADV
Hedge funds managed
1112 private funds in total
Employees
189Form ADV Item 5.A
Registration
SEC-registered adviserCRD 157876
Latest Form ADV
07/31/2026Disciplinary disclosures: yes, see SEC record

Estimated 13F portfolio performance

Estimated by AltMountain, derived from the firm’s public Form 13F filings. Not reported by the firm and not the return of any fund.

Estimated from 13F · 2026 YTD+17.7%Through Q2 2026 · S&P 500 +9.5%
Estimated from 13F · 4 quarters+66.2%Q3 2025 – Q2 2026
S&P 500+20.9%Same quarters, price only
13F holdings$8.0 billion72 positions, 2026-06-30
$100$133$166Q3 2025Q4 2025Q1 2026Q2 202613F est. $166S&P 500 $121
QuarterEst. 13F returnS&P 500
Q2 2026+16.2%+14.8%
Q1 2026+1.3%-4.6%
Q4 2025+23.7%+2.4%
Q3 2025+14.2%+7.8%

Estimate of the firm's disclosed long U.S. stock portfolio from its quarterly 13F filings, holding each quarter-end portfolio to the next quarter-end at prices implied by all 13F filers. It is a price return before dividends and fees, ignores shorts, options, bonds, cash and trading within the quarter, and is not the return of any fund. Disclosures

Manager of this firm? Report your fund’s actual net return, or email hello@altmountain.com to correct or remove this estimate. Removal requests from the firm are honored.

13F holdings as of Sep 30, 2026

The 50 largest of 67 share positions ($5,123,201,110) reported by Deerfield Management Company, L.P. on Form 13F for the quarter ended Sep 30, 2026, filed Nov 16, 2026. Shown as filed with the SEC. Original filing on SEC.gov ↗ The estimated return above runs through Jun 30, 2026; it is updated when the SEC publishes its complete data for the quarter.

Share of the reported 13F portfolio, ten largest positions

  • Revolution Medicines Inc8.51%
  • Centene Corp Del5.94%
  • United Therapeutics Corp Del5.72%
  • Praxis Precision Medicines I5.48%
  • Genmab A/s4.78%
  • Viatris Inc3.78%
  • Cogent Biosciences Inc3.72%
  • Celcuity Inc3.72%
  • Legend Biotech Corp3.16%
  • Vera Therapeutics Inc2.73%
StockValue% of 13F portfolioSharesShares vs prior quarter
Revolution Medicines Inc$435,972,2408.51%2,124,000-11.20%
Centene Corp Del$304,450,1205.94%4,901,000Unchanged
United Therapeutics Corp Del$292,944,6505.72%540,598+18.29%
Praxis Precision Medicines I$280,556,7125.48%963,351Unchanged
Genmab A/s$244,908,8754.78%6,865,000Unchanged
Viatris Inc$193,821,3603.78%10,938,000-45.87%
Cogent Biosciences Inc$190,743,1403.72%5,957,000+18.99%
Celcuity Inc$190,662,2413.72%2,397,664+65.24%
Legend Biotech Corp$161,857,6203.16%8,137,638Unchanged
Vera Therapeutics Inc$140,099,1422.73%4,338,778+10.78%
Tango Therapeutics Inc$129,241,0002.52%5,180,000+23.61%
Biocryst Pharmaceuticals Inc$129,039,4302.52%15,490,928+2.61%
Brookdale SR Living Inc$126,029,0572.46%11,637,032Unchanged
Biomarin Pharmaceutical Inc$121,508,7602.37%2,025,146+51.94%
Ionis Pharmaceuticals Inc$118,798,8712.32%2,660,669-10.40%
Larimar Therapeutics Inc$113,764,2822.22%35,606,974Unchanged
Newamsterdam Pharma Company$103,464,9162.02%4,254,314-0.25%
Mineralys Therapeutics Inc$99,464,5401.94%3,958,000Unchanged
Boston Scientific Corp$93,211,9561.82%2,135,440+62.39%
Chemed Corp New$91,922,7401.79%182,000+506.67%
Inspire Med SYS Inc$89,950,3481.76%1,296,862Unchanged
Bio Rad Labs Inc$85,388,9001.67%226,070Unchanged
Pharvaris N V$82,154,8001.60%2,590,000-23.28%
Dianthus Therapeutics Inc$80,477,7001.57%914,000-18.78%
Ideaya Biosciences Inc$76,955,2601.50%2,003,000-26.21%
Syndax Pharmaceuticals Inc$71,062,1201.39%3,779,900Unchanged
Savara Inc$70,016,0401.37%13,569,000Unchanged
Certara Inc$69,118,9381.35%7,512,928Unchanged
Acadia Healthcare Company In$68,573,6981.34%2,493,589-44.83%
Adapthealth Corp$64,734,3971.26%11,477,730Unchanged
Parabilis Medicines Inc$60,727,9321.19%1,880,704Unchanged
Xenon Pharmaceuticals Inc$60,087,7341.17%1,615,696Unchanged
Arrowhead Pharmaceuticals In$55,178,4731.08%843,063-39.31%
Envista Holdings Corporation$51,871,0471.01%2,210,100Unchanged
Stoke Therapeutics Inc$47,411,0000.93%1,823,500Unchanged
Zoetis Inc$44,132,5600.86%632,000New
Disc Medicine Inc$43,007,2200.84%657,000Unchanged
Beta Bionics Inc$36,132,4160.71%1,903,710+43.78%
Structure Therapeutics Inc$33,959,2200.66%1,086,000Unchanged
Ars Pharmaceuticals Inc$32,341,4300.63%7,503,812Unchanged
Belite Bio Inc$32,265,8000.63%190,000-46.81%
Cooper Cos Inc$31,487,2100.61%557,000New
Blossomhill Therapeutics Inc$26,953,4400.53%1,446,000New
Odyssey Therapeutics Inc$23,245,2090.45%1,046,139Unchanged
Tandem Diabetes Care Inc$22,685,7260.44%1,390,909New
The Oncology Institute Inc$21,235,5290.41%3,360,052Unchanged
Avalyn Pharmaceuticals Inc$20,826,1900.41%731,000Unchanged
Alamar Biosciences Inc$20,442,0000.40%600,000Unchanged
Tyra Biosciences Inc$16,017,4130.31%732,392-27.99%
Foghorn Therapeutics Inc$15,687,8900.31%4,394,367Unchanged

Changes since Jun 30, 2026

Comparing the share counts in the two quarter-end filings: 7 new positions, 12 sold out, 10 increased, 14 reduced and 36 unchanged.

Number of positions (a count, not dollars)

  • New positions7
  • Increased10
  • Unchanged36
  • Reduced14
  • Sold out12

New positions

StockValueShares
Zoetis Inc$44,132,560632,000
Cooper Cos Inc$31,487,210557,000
Blossomhill Therapeutics Inc$26,953,4401,446,000
Tandem Diabetes Care Inc$22,685,7261,390,909
Vogenx Inc$14,487,763635,707
Alignment Healthcare Inc$9,566,9311,172,418
Electra Therapeutics Inc$7,875,000700,000

Sold out

StockValue at Jun 30, 2026Shares held then
Nuvalent Inc$2,130,183,57517,248,450
Lantheus Hldgs Inc$83,537,709752,999
Pfizer Inc$73,203,2003,040,000
Indivior Pharmaceuticals Inc$67,654,1621,648,895
Caredx Inc$56,932,1131,997,618
Sionna Therapeutics Inc$29,953,495680,916
Alnylam Pharmaceuticals Inc$20,450,47367,935
Kyverna Therapeutics Inc$17,820,0002,000,000
Spyglass Pharma Inc$12,243,000550,000
Mobia Med Inc$8,988,077670,752
Veracyte Inc$5,931,730101,000
Surrozen Inc$2,750166,666

Largest increases

StockChange in sharesChangeValue nowShares now
Chemed Corp New+152,000+506.67%$91,922,740182,000
Celcuity Inc+946,650+65.24%$190,662,2412,397,664
United Therapeutics Corp Del+83,598+18.29%$292,944,650540,598
Biomarin Pharmaceutical Inc+692,310+51.94%$121,508,7602,025,146
Boston Scientific Corp+820,440+62.39%$93,211,9562,135,440
Cogent Biosciences Inc+950,896+18.99%$190,743,1405,957,000
Tango Therapeutics Inc+989,389+23.61%$129,241,0005,180,000
Vera Therapeutics Inc+422,378+10.78%$140,099,1424,338,778
Beta Bionics Inc+579,710+43.78%$36,132,4161,903,710
Biocryst Pharmaceuticals Inc+394,525+2.61%$129,039,43015,490,928

Largest reductions

StockChange in sharesChangeValue nowShares now
Viatris Inc-9,268,170-45.87%$193,821,36010,938,000
Acadia Healthcare Company In-2,026,411-44.83%$68,573,6982,493,589
Revolution Medicines Inc-268,000-11.20%$435,972,2402,124,000
Arrowhead Pharmaceuticals In-545,992-39.31%$55,178,473843,063
Belite Bio Inc-167,199-46.81%$32,265,800190,000
Ideaya Biosciences Inc-711,503-26.21%$76,955,2602,003,000
Pharvaris N V-786,042-23.28%$82,154,8002,590,000
Dianthus Therapeutics Inc-211,313-18.78%$80,477,700914,000
Monopar Therapeutics Inc-186,154-57.50%$10,961,875137,591
Ionis Pharmaceuticals Inc-308,834-10.40%$118,798,8712,660,669
Bridgebio Oncology Therapeut-1,747,279-35.77%$12,866,4853,138,167
Tyra Biosciences Inc-284,608-27.99%$16,017,413732,392
Bright Minds Biosciences Inc-46,705-16.50%$11,772,217236,295
Newamsterdam Pharma Company-10,475-0.25%$103,464,9164,254,314

Each list shows up to 20 positions, largest first by dollar amount. Changes compare two quarter-end snapshots, with the earlier share count adjusted for stock splits AltMountain detected. They do not show when, or at what price, anything was bought or sold.

From public Form 13F filings, not verified. Form 13F is filed up to 45 days after the quarter ends, so positions may have changed. It lists only certain long positions in U.S.-listed stocks and exchange-traded funds; options are not shown here, and short positions, most bonds, cash, non-U.S. securities and private investments are not reported at all, so a holding may be one side of a hedge. A filing covers the manager as a whole, not any single fund, and filings contain errors. This is not investment advice or a recommendation to buy or sell any security. Disclosures

Hedge funds filing Form D (1)

Matched to this firm by the fund names and related persons in each Form D. The list may be incomplete.

Private equity funds filing Form D (1)

Matched to this firm by the fund names and related persons in each Form D. The list may be incomplete.

Private funds reported on Form ADV (11)

Fund
Gross assets
Minimum
Owners
Adviser
Deerfield Partners, L.P.
Delaware, United StatesHedge fund
Gross assets$6.2B
Minimum$1.0M
Owners171
AdviserDeerfield Management Company
Deerfield Private Design Fund IV, L.P.
Delaware, United StatesHedge fund
Gross assets$3.7B
Minimum$1.0M
Owners203
AdviserDeerfield Management Company
Deerfield Private Design Fund III, L.P.
Delaware, United StatesHedge fund
Gross assets$1.8B
Minimum$1.0M
Owners152
AdviserDeerfield Management Company
Deerfield Healthcare Innovations Fund, L.P.
Delaware, United StatesHedge fund
Gross assets$1.5B
Minimum$1.0M
Owners124
AdviserDeerfield Management Company
Deerfield Private Design Fund V, L.P.
Delaware, United StatesHedge fund
Gross assets$1.5B
Minimum$1.0M
Owners95
AdviserDeerfield Management Company
Deerfield Healthcare Innovations Fund II, L.P.
Delaware, United StatesHedge fund
Gross assets$882M
Minimum$1.0M
Owners96
AdviserDeerfield Management Company
Deerfield Healthcare Innovations Fund III, L.P.
Delaware, United StatesHedge fund
Gross assets$334M
Minimum$1.0M
Owners36
AdviserDeerfield Management Company
Deerfield Private Design Fund II, L.P.
Delaware, United StatesHedge fund
Gross assets$118M
Minimum$1.0M
Owners62
AdviserDeerfield Management Company
Deerfield Private Design International II, L.P.
British Virgin IslandsHedge fund
Gross assets$113M
Minimum$1.0M
Owners42
AdviserDeerfield Management Company
Deerfield Pdi Financing II, L.P.
British Virgin IslandsPrivate equity fund
Gross assets$21.8M
Minimum$1.0M
Owners42
AdviserDeerfield Management Company
Deerfield Healthcare Innovations Fund III-A, L.P.
Delaware, United StatesHedge fund
Gross assets$15.9M
Minimum$1.0M
Owners5
AdviserDeerfield Management Company

As reported in the adviser's Form ADV filed Mar 28, 2024. Funds also listed from Form D are shown above.

From SEC filings. Firm data comes from the SEC's Form ADV data as of Oct 2, 2026; performance estimates come from Form 13F. AltMountain has not verified this information, and it is not an offer, solicitation or recommendation. Full disclosures⁠​​‌‌‌‌‌‌‌​‌‌‌‌‌‌‌‌​‌⁠